— Know what they know.
Not Investment Advice

NSISBC.XD DXE

Novonesis (Novozymes) B
1W: -1.6% 1M: -7.6% 3M: -2.5% YTD: +7.9% 1Y: -0.6%
kr 422.00 ($63.27)
+4.60 (+1.10%)
 
Weekly Expected Move ±3.1%
kr 391 kr 404 kr 417 kr 431 kr 444
DXE · Basic Materials · Chemicals - Specialty · Tech Score Sell · Power 37 · kr 116.0B mcap

Income Trends

Revenue
$28.6B +59.7% ▲
5Y CAGR: +14.7%
Gross Profit
$14.9B +52.9% ▲
5Y CAGR: +13.2%
Operating Income
$3.7B -6.0% ▼
5Y CAGR: +0.8%
Net Income
$2.3B -24.6% ▼
5Y CAGR: -6.3%
EPS (Diluted)
$8.21 -24.5% ▼
5Y CAGR: -5.7%
EBITDA
$8.1B +43.3% ▲
5Y CAGR: +12.0%

Profit Margins

Year-over-Year Growth

View Full Income Statement
Line ItemFY2020FY2021FY2022FY2023FY2024
Revenue$14.0B$15.0B$17.6B$17.9B$28.6B
YoY Growth-2.5%+6.7%+17.4%+2.0%+59.7%
Cost of Revenue$6.2B$6.3B$8.0B$8.2B$13.7B
Gross Profit$7.9B$8.6B$9.6B$9.7B$14.9B
Gross Margin56.0%57.8%54.6%54.3%52.0%
R&D Expenses$1.9B$2.0B$2.0B$2.0B$3.1B
SG&A Expenses$2.3B$2.8B$3.2B$3.3B$5.7B
Operating Expenses$4.2B$4.6B$5.0B$5.7B$11.1B
Operating Income$3.7B$4.0B$4.6B$4.0B$3.7B
Operating Margin26.1%26.8%26.0%22.2%13.1%
Interest Expense$0$0$0$0$600M
Income Before Tax$3.5B$3.9B$4.6B$3.9B$3.1B
Tax Expense$695M$779M$870M$870M$830M
Net Income$2.8B$3.1B$3.7B$3.0B$2.3B
Net Margin20.2%21.0%20.9%16.9%8.0%
EPS (Diluted)$10.02$11.23$13.19$10.88$8.21
EBITDA$4.7B$5.1B$5.7B$5.6B$8.1B
Shares Outstanding282M280M279M278M278M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms